{
    "clinical_study": {
        "@rank": "18341", 
        "arm_group": [
            {
                "arm_group_label": "Single-hormone closed-loop system", 
                "arm_group_type": "Active Comparator", 
                "description": "In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels"
            }, 
            {
                "arm_group_label": "Dual-hormone closed-loop system", 
                "arm_group_type": "Active Comparator", 
                "description": "In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels"
            }
        ], 
        "brief_summary": {
            "textblock": "Closed-loop strategy is composed of three components: glucose sensor to read glucose levels,\n      insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required\n      insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would\n      regulate glucose levels through the infusion of two hormones: insulin and glucagon.\n\n      The objective is to compare the efficacy of single-hormone closed-loop strategy and\n      dual-hormone closed-loop strategy at regulating glucose levels during continuous exercise\n      and interval exercise.\n\n      The investigator hypothesized that dual-hormone closed-loop strategy is superior to\n      single-hormone closed-loop strategy in regulating glucose levels during exercise periods."
        }, 
        "brief_title": "Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "Closed-loop strategy is composed of three components: glucose sensor to read glucose levels,\n      insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required\n      insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would\n      regulate glucose levels through the infusion of two hormones: insulin and glucagon.\n\n      We aim to conduct a randomized two-way cross-over trial comparing single-hormone closed-loop\n      strategy and dual-hormone closed-loop strategy to compare the two interventions during\n      exercise periods in adults with type 1 diabetes. A moderate intensity exercise will be\n      performed for 60 minutes at 60% of the maximum oxygen consumption (VO2max). A high intensity\n      exercise will be 40 minutes of interval training. The interval training will be preceded by\n      a 10 minutes warm-up and followed by a 10 minutes cool down."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females \u2265 18 years of old.\n\n          -  Clinical diagnosis of type 1 diabetes for at least one year.\n\n          -  The subject will have been on insulin pump therapy for at least 3 months.\n\n          -  Last (less than 3 months) HbA1c \u2264 12%.\n\n        Exclusion Criteria:\n\n          -  Clinically significant microvascular complications: nephropathy (estimated glomerular\n             filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or\n             severe proliferative retinopathy as judged by the investigator.\n\n          -  Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac\n             surgery.\n\n          -  Ongoing pregnancy.\n\n          -  Severe hypoglycemic episode within two weeks of screening.\n\n          -  Other serious medical illness likely to interfere with study participation or with\n             the ability to complete the exercise periods by the judgment of the investigator\n             (e.g. orthopedic limitation).\n\n          -  Failure to comply with team's recommendations (e.g. not willing to eat snack, not\n             willing to change pump parameters, etc).\n\n          -  Problems with venous access"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930110", 
            "org_study_id": "CLASS-06"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Single-hormone closed-loop system", 
                    "Dual-hormone closed-loop system"
                ], 
                "description": "Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.", 
                "intervention_name": "60-minute exercise", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Single-hormone closed-loop system", 
                    "Dual-hormone closed-loop system"
                ], 
                "description": "Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.", 
                "intervention_name": "40-minute interval exercise", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 1 diabetes", 
            "Hypoglycemia", 
            "Insulin", 
            "Glucagon", 
            "Closed-loop system", 
            "Artificial pancreas"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "last_name": "Virginie Messier, MsC", 
                "phone": "514-987-5500", 
                "phone_ext": "3227"
            }, 
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H2W 1R7"
                }, 
                "name": "Institut de recherches cliniques de Montr\u00e9al"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Cross-over Study to Compare the Efficacy of Single-hormone Closed-loop Strategy and Dual-hormone Closed-loop Strategy at Regulating Glucose Levels During Continuous Exercise and Interval Exercise in Adults With Type-1 Diabetes", 
        "overall_contact": {
            "email": "virginie.messier@ircm.qc.ca", 
            "last_name": "Virginie Messier", 
            "phone": "514-987-5500", 
            "phone_ext": "3227"
        }, 
        "overall_official": {
            "affiliation": "Institut de recherches cliniques de Montr\u00e9al", 
            "last_name": "R\u00e9mi Rabasa-Lhoret, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number of patients experiencing exercise-induced hypoglycemia requiring dextrose infusion (< 3.3 mmol/L symptomatic or < 3.0 mmol/L regardless of symptoms).", 
            "safety_issue": "No", 
            "time_frame": "18:00 hours to 19:30 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930110"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institut de Recherches Cliniques de Montreal", 
            "investigator_full_name": "R\u00e9mi Rabasa-Lhoret", 
            "investigator_title": "Associate professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference between glucose levels at the beginning of the exercise and the lowest glucose level from the start of the exercise until 30 minutes after exercise).", 
                "measure": "Decrease in glucose levels during each exercise", 
                "safety_issue": "No", 
                "time_frame": "18:00 to 19:30  hours or 18:00 to 19:10 depending on the exercise performed"
            }, 
            {
                "measure": "Area under the curve of plasma glucose levels < 4 mmol/L", 
                "safety_issue": "No", 
                "time_frame": "15:30  hours to 19:30 hours"
            }, 
            {
                "measure": "Percentage of time of plasma glucose levels < 4 mmol/L", 
                "safety_issue": "No", 
                "time_frame": "15:30 hours  to 19:30 hours"
            }, 
            {
                "measure": "Number of patients with an exercise-induced hypoglycemia < 3.9 mmol/L", 
                "safety_issue": "No", 
                "time_frame": "15:30  hours to 19:30 hours"
            }, 
            {
                "measure": "Decremental area under the curve from the start of the exercise for 90 minutes.", 
                "safety_issue": "No", 
                "time_frame": "18:00 to 19:30"
            }, 
            {
                "measure": "Percentage of time-in-target defined as between 4 and 10 mmol/L", 
                "safety_issue": "No", 
                "time_frame": "15:30  hours to 19:30 hours"
            }, 
            {
                "measure": "Mean time (minutes) to the first hypoglycemic event during the exercise period", 
                "safety_issue": "No", 
                "time_frame": "18:00 to 19:00"
            }, 
            {
                "measure": "The amount of dextrose infused", 
                "safety_issue": "No", 
                "time_frame": "15:30 to 19:30"
            }
        ], 
        "source": "Institut de Recherches Cliniques de Montreal", 
        "sponsors": {
            "collaborator": {
                "agency": "Soci\u00e9t\u00e9 Francophone du Diab\u00e8te", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Institut de Recherches Cliniques de Montreal", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}